エピジェネティクス診断の世界市場：市場規模・シェア・動向分析 (製品別・技術別・用途別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

エピジェネティクス診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のエピジェネティクス診断市場は2030年までに391億5,000万米ドルに達すると予測され、2025年から2030年にかけて15.5%のCAGRで拡大すると予測されています。

この成長は、エピジェネティクスの研究開発のための投資、資金調達、承認の増加、およびMDD（大うつ病性障害）の有病率の増加に起因しています。世界保健機関（WHO）によると、2023年には成人の約5％がうつ病性障害を経験しています。さらに、2022年に国立生物工学情報センター（NCBI）が発表した研究では、世界中で約2億8,000万人がMDDに罹患していると報告されています。創薬や開発におけるエピジェネティクスの応用は拡大しており、ゲノム配列決定はより安価になってきています。さらに、エピジェネティック創薬に関連する技術の進歩もこの成長に寄与しています。

さらに、エピジェネティクスに対する公的機関および民間機関の両方からの投資の増加が、2023年から2030年までの市場成長を促進すると予想されます。2025年2月、TruDiagnostic社は、DNAメチル化、長寿科学、診断イノベーションに取り組む研究者を支援するために40万米ドルの資金を提供する助成金を導入しました。2022年にNCBIが発表した研究では、エピジェネティック修飾は細胞の恒常性とゲノムの維持に重要な役割を果たし、ウイルス感染の原因と開発に関する情報を提供すると述べられています。

エピジェネティクス診断市場：分析概要

• 2024年の製品別シェアは試薬が30.0%以上を占め、エピジェネティクス研究での高い使用率による。
• DNAメチル化セグメントは、予測期間2025年～2030年に44.5%のCAGRで最速の成長が見込まれます。
• 2024年の市場シェアはがん分野が最大で、がん罹患率の増加により、エピジェネティクス市場は予測期間中に成長すると予測されます。
• 学術研究セグメントは、2024年に最大の市場シェアを占めました。この成長は、さまざまな企業による研究開発への資金提供の増加や政府による支援イニシアティブなどの要因によるものです。
• 北米は、大手企業の存在と高度な医療インフラにより、2024年のエピジェネティック診断市場をリードしました。さらに、認知度の向上と多額の研究開発費が、予測期間を通じて成長を促進すると予測されています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 エピジェネティクス診断市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• エピジェネティクス診断市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析
• エピジェネティクス診断市場：パイプライン分析

第4章 エピジェネティクス診断市場：製品別の推定・動向分析

• 製品別のダッシュボード
• エピジェネティクス診断市場：製品別の変動分析
• 世界のエピジェネティクス診断の市場規模と動向分析：製品別（2018～2030年）
• 試薬
• キット
  • ChIPシーケンシングキット
  • 全ゲノム増幅キット
  • 亜硫酸水素塩変換キット
  • RNAシーケンシングキット
  • その他
• 装置
• 酵素
• サービス

第5章 エピジェネティクス診断市場：技術別の推定・動向分析

• 技術別のダッシュボード
• エピジェネティクス診断市場：技術別の変動分析
• エピジェネティクス診断の市場規模と動向分析：技術別（2018～2030年）
• DNAメチル化
  • 試薬
  • キット
  • 機器
  • 酵素
  • サービス
• ヒストンメチル化
  • 試薬
  • キット
  • 装置
  • 酵素
  • サービス
• ヒストンアセチル化
  • 試薬
  • キット
  • 装置
  • 酵素
  • サービス
• 長鎖ノンコーディングRNA (lncRNA)
  • 試薬
  • キット
  • 装置
  • 酵素
  • サービス
• マイクロRNAの修飾
  • 試薬
  • キット
  • 装置
  • 酵素
  • サービス
• クロマチン構造
  • 試薬
  • キット
  • 装置
  • 酵素
  • サービス

第6章 エピジェネティクス診断市場：用途別の推定・動向分析

• 用途別のダッシュボード
• エピジェネティクス診断市場：用途別の変動分析
• 世界のエピジェネティクス診断の市場規模と動向分析：用途別（2018～2030年）
• 腫瘍
  • 固形腫瘍
  • 液体腫瘍
• 腫瘍以外
  • 炎症性疾患
  • 代謝性疾患
  • 感染症
  • 心血管疾患
  • その他

第7章 エピジェネティクス診断市場：最終用途別の推定・動向分析

• 最終用途別のダッシュボード
• エピジェネティクス診断市場：最終用途別の変動分析
• 世界のエピジェネティクス診断の市場規模と動向分析：最終用途別（2018～2030年）
• 学術研究
• 臨床研究
• 病院・診療所
• 製薬・バイオテクノロジー企業
• その他のユーザー

第8章 エピジェネティクス診断市場：地域別の推定・動向分析

• 市場ダッシュボード：地域別
• 市場シェア分析：地域別（2024年・2030年）
• エピジェネティクス診断市場：主なポイント、地域別
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業のヒートマップ分析（2024年）
• 企業プロファイル
  • Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • Eisai Co. Ltd.
  • Novartis AG
  • Element Bisosciences, Inc.
  • Cantata Bio（Dovetail Genomics LLC.）
  • Illumina, Inc.
  • ValiRx Plc.
  • Abcam Ltd.

List of Tables

• Table 1 List of abbreviations
• Table 2 Epigenetics Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 3 Global epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 4 Global epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 5 Global epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 6 Global epigenetics diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 7 North America epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 8 North America epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 9 North America epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 10 North America epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 11 North America epigenetics diagnostics market, by country, 2018 - 2030 (USD Million)
• Table 12 U.S. epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 13 U.S. epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 14 U.S. epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 15 U.S. epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 16 Canada epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 17 Canada epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 18 Canada epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 19 Canada epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 20 Mexico epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 21 Mexico epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 22 Mexico epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 23 Mexico epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 24 Europe epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 25 Europe epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 26 Europe epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 27 Europe epigenetics diagnostics market, by country, 2018 - 2030 (USD Million)
• Table 28 Europe epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 29 Germany epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 30 Germany epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 31 Germany epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 32 Germany epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 33 UK epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 34 UK epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 35 UK epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 36 UK epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 37 France epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 38 France epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 39 France epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 40 France epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 41 Italy epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 42 Italy epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 43 Italy epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 44 Italy epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 45 Spain epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 46 Spain epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 47 Spain epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 48 Spain epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 49 Denmark epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 50 Denmark epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 51 Denmark epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 52 Denmark epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 53 Sweden epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 54 Sweden epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 55 Sweden epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 56 Sweden epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 57 Norway epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 58 Norway epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 59 Norway epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 60 Norway epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific epigenetics diagnostics market, by country, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 66 China epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 67 China epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 68 China epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 69 China epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 70 Japan epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 71 Japan epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 72 Japan epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 73 Japan epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 74 India epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 75 India epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 76 India epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 77 India epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 78 South Korea epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 79 South Korea epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 80 South Korea epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 81 South Korea epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 82 Australia epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 83 Australia epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 84 Australia epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 85 Australia epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 86 Thailand epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 87 Thailand epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 88 Thailand epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 89 Thailand epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 90 Latin America epigenetics diagnostics market, by country, 2018 - 2030 (USD Million)
• Table 91 Latin America epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 92 Latin America epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 93 Latin America epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 94 Latin America epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 95 Brazil epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 96 Brazil epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 97 Brazil epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 98 Brazil epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 99 Argentina epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 100 Argentina epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 101 Argentina epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 102 Argentina epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 103 MEA epigenetics diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 104 MEA epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 105 MEA epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 106 MEA epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 107 MEA epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 108 South Africa epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 109 South Africa epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 110 South Africa epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 111 South Africa epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 116 UAE epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 117 UAE epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 118 UAE epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 119 UAE epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 120 Kuwait epigenetics diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 121 Kuwait epigenetics diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 122 Kuwait epigenetics diagnostics market, by application, 2018 - 2030 (USD Million)
• Table 123 Kuwait epigenetics diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Epigenetics diagnostics market: market outlook
• Fig. 10 Epigenetics diagnostics competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 Epigenetics diagnostics market driver impact
• Fig. 16 Epigenetics diagnostics market restraint impact
• Fig. 17 Epigenetics diagnostics market strategic initiatives analysis
• Fig. 18 Epigenetics diagnostics market: Technology movement analysis
• Fig. 19 Epigenetics diagnostics market: Technology outlook and key takeaways
• Fig. 20 DNA methylation market estimates and forecast, 2018 - 2030
• Fig. 21 Histone methylation estimates and forecast, 2018 - 2030
• Fig. 22 Histone acetylation market estimates and forecast, 2018 - 2030
• Fig. 23 Large non - coding RNA estimates and forecast, 2018 - 2030
• Fig. 24 MircoRNA modification market estimates and forecast, 2018 - 2030
• Fig. 25 Chromatin structures estimates and forecast, 2018 - 2030
• Fig. 26 Epigenetics diagnostics market: Product movement analysis
• Fig. 27 Epigenetics diagnostics market: Product outlook and key takeaways
• Fig. 28 Reagents market estimates and forecasts, 2018 - 2030
• Fig. 29 Kits market estimates and forecasts,2018 - 2030
• Fig. 30 ChIP Sequencing kit market estimates and forecasts,2018 - 2030
• Fig. 31 Whole Genomic Amplification kit market estimates and forecasts,2018 - 2030
• Fig. 32 Bisulfite Conversion kit market estimates and forecasts,2018 - 2030
• Fig. 33 RNA Sequencing kit market estimates and forecasts,2018 - 2030
• Fig. 34 Others market estimates and forecasts,2018 - 2030
• Fig. 35 Instruments market estimates and forecasts,2018 - 2030
• Fig. 36 Enzymes market estimates and forecasts,2018 - 2030
• Fig. 37 Service market estimates and forecasts,2018 - 2030
• Fig. 38 Epigenetics diagnostics market: Application movement analysis
• Fig. 39 Epigenetics diagnostics market: Application outlook and key takeaways
• Fig. 40 Oncology market estimates and forecasts, 2018 - 2030
• Fig. 41 Solid tumors market estimates and forecasts, 2018 - 2030
• Fig. 42 Liquid tumors market estimates and forecasts, 2018 - 2030
• Fig. 43 Non - oncology market estimates and forecasts,2018 - 2030
• Fig. 44 Inflammatory diseases market estimates and forecasts, 2018 - 2030
• Fig. 45 Metabolic diseases market estimates and forecasts, 2018 - 2030
• Fig. 46 Infectious diseases market estimates and forecasts, 2018 - 2030
• Fig. 47 Cardiovascular diseases market estimates and forecasts, 2018 - 2030
• Fig. 48 Others market estimates and forecasts, 2018 - 2030
• Fig. 49 Epigenetics diagnostics market: End use movement analysis
• Fig. 50 Epigenetics diagnostics market: End use outlook and key takeaways
• Fig. 51 Academic research market estimates and forecasts, 2018 - 2030
• Fig. 52 Clinical research market estimates and forecasts, 2018 - 2030
• Fig. 53 Hospitals & clinics market estimates and forecasts, 2018 - 2030
• Fig. 54 Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 - 2030
• Fig. 55 Other users market estimates and forecasts, 2018 - 2030
• Fig. 56 Global epigenetics diagnostics market: Regional movement analysis
• Fig. 57 Global epigenetics diagnostics market: Regional outlook and key takeaways
• Fig. 58 North America market estimates and forecasts, 2018 - 2030
• Fig. 59 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 60 Canada market estimates and forecasts, 2018 - 2030
• Fig. 61 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 62 Europe market estimates and forecasts, 2018 - 2030
• Fig. 63 UK market estimates and forecasts, 2018 - 2030
• Fig. 64 Germany market estimates and forecasts, 2018 - 2030
• Fig. 65 France market estimates and forecasts, 2018 - 2030
• Fig. 66 Italy market estimates and forecasts, 2018 - 2030
• Fig. 67 Spain market estimates and forecasts, 2018 - 2030
• Fig. 68 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 70 Norway market estimates and forecasts, 2018 - 2030
• Fig. 71 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 72 China market estimates and forecasts, 2018 - 2030
• Fig. 73 Japan market estimates and forecasts, 2018 - 2030
• Fig. 74 India market estimates and forecasts, 2018 - 2030
• Fig. 75 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 76 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 77 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 78 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 79 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 80 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 81 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 82 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 83 UAE market estimates and forecasts, 2018 - 2030
• Fig. 84 Kuwait market estimates and forecasts, 2018 - 2030

Epigenetics Diagnostics Market Growth & Trends:

The global epigenetics diagnostics market is anticipated to reach USD 39.15 billion by 2030 and is anticipated to expand at a CAGR of 15.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to increased investment, funding, and approvals for epigenetics research and development, and the increasing prevalence of MDD (Major Depressive Disorder). According to the World Health Organization (WHO), in 2023, approximately 5% of adults experienced depressive disorders. Furthermore, a study published by the National Center for Biotechnology Information (NCBI) in 2022 reported that around 280 million people worldwide are affected by MDD. Epigenetics' applications in drug discovery and development are growing, and genome sequencing is becoming more affordable. Additionally, advancements in technology related to epigenetic drug discovery contribute to this growth.

Additionally, an increase in investment from both public and private organizations in epigenetics is expected to drive market growth from 2023 to 2030. In February 2025, TruDiagnostic introduced the grant, which provides USD 400,000 in funding to support researchers working in DNA methylation, longevity science, and diagnostic innovation. A study published by NCBI in 2022 stated that epigenetic modification plays a crucial role in maintaining cellular homeostasis and the genome and provides information about the cause and development of virus infection.

Epigenetics Diagnostics Market Report Highlights:

• Reagents dominated the product segment with more than 30.0% share in 2024, owing to their high usage in epigenetic research studies.
• The DNA Methylation segment is expected to grow at the fastest CAGR of 44.5% over the forecast period 2025 - 2030.
• The oncology segment held the largest market share in 2024, and with the increasing incidence of cancer, the epigenetic market is expected to grow over the forecast period.
• The academic research segment held the largest market share in 2024. The growth is attributed to the factors such as increased funding for research and development by various companies and supportive initiatives from the government.
• North America led the epigenetic diagnostics market in 2024 due to the presence of key market players and an advanced healthcare infrastructure. Additionally, increasing awareness along with significant R&D expenditure is expected to fuel growth throughout the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Technology
  • 2.2.3. Application
  • 2.2.4. End Use
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Epigenetics Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Epigenetics Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Epigenetics Diagnostics Market: Pipeline Analysis

Chapter 4. Epigenetics Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Epigenetics Diagnostics Market: Product Movement Analysis
• 4.3. Global Epigenetics Diagnostics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Reagents
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Kits
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. ChIP Sequencing Kit
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Whole Genomic Amplification kit
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Bisulfite Conversion kit
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. RNA Sequencing kit
    • 4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.6. Others
    • 4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million
• 4.6. Instruments
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Services
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Epigenetics Diagnostics Market: Technology Estimates & Trend Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Epigenetics Diagnostics Market: Technology Movement Analysis
• 5.3. Epigenetics Diagnostics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. DNA Methylation
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Reagents
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Kits
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Instruments
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Enzymes
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Services
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Histone Methylation
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Reagents
    • 5.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Kits
    • 5.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Instruments
    • 5.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Enzymes
    • 5.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Services
    • 5.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Histone Acetylation
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Reagents
    • 5.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. Kits
    • 5.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Instruments
    • 5.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.5. Enzymes
    • 5.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Services
    • 5.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Large non - coding RNA
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Reagents
    • 5.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. Kits
    • 5.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.4. Instruments
    • 5.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.5. Enzymes
    • 5.7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.6. Services
    • 5.7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. MicroRNA modification
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Reagents
    • 5.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.3. Kits
    • 5.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.4. Instruments
    • 5.8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.5. Enzymes
    • 5.8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.6. Services
    • 5.8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Chromatin structure
  • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.2. Reagents
    • 5.9.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.3. Kits
    • 5.9.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.4. Instruments
    • 5.9.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.5. Enzymes
    • 5.9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.6. Services
    • 5.9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Epigenetics Diagnostics Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Epigenetics Diagnostics Market: Application Movement Analysis
• 6.3. Global Epigenetics Diagnostics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Solid tumors
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Liquid tumors
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Non - Oncology
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Inflammatory diseases
    • 6.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Metabolic diseases
    • 6.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Infectious diseases
    • 6.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Cardiovascular diseases
    • 6.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Others
    • 6.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Epigenetics Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. Application Segment Dashboard
• 7.2. Epigenetics Diagnostics Market: End Use Movement Analysis
• 7.3. Global Epigenetics Diagnostics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Academic Research
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Clinical Research
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Hospitals & Clinics
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Pharmaceutical & Biotechnology Companies
  • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other Users
  • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Epigenetics Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2030
• 8.3. Continuous bioprocessing market by Region: Key Takeaways
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Denmark
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Norway
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework/ reimbursement structure
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company heat map analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Hoffmann- La Roche Ltd.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Thermo Fisher Scientific, Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Eisai Co. Ltd.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Novartis AG
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Element Bisosciences, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Cantata Bio (Dovetail Genomics LLC.)
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Illumina, Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. ValiRx Plc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Abcam Ltd.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives